506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Todd M. Zimmerman, MD
University of Chicago
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Chicago Cancer Research Center
Chicago, Illinois, United States
- Holden Comprehensive Cancer Center at the University of Iowa
Iowa City, Iowa, United States
- Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 1999
- Primary completion
- 31 Jan 2002
- Completion
- 31 Jan 2002
- Last update posted
- 4 Jul 2016
- Registered enrollment
- 10
- Registry id
- NCT00004239
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.